3376-24-7
3376-24-7 結(jié)構(gòu)式
基本信息
N-叔丁基-#-苯基硝酮
N-叔丁基-а-苯基硝酮
N-苯亞甲基叔丁胺-N-氧化物
N-叔丁基-Α-苯基硝酮
N-叔丁基-A-苯硝酮
N-叔丁基-Α-苯基硝酸靈
N-BENZYLIDENE-TERT-BUTYLAMINE N-OXIDE
N-T-BUTYL-ALPHA-PHENYLNITRONE
N-TERT-BUTYL-ALPHA-PHENYLNITRONE
N-TERT-BUTYL-A-PHENYLNITRONE
PBN
PHENYL N-TERT-BUTYLNITRONE
2-methyl-n-(phenylmethylene)-2-propanaminn-oxide
2-methyl-n-(phenylmethylene)-s-propanaminen-oxide
2-methyl-n-(phenylmethylene)-s-propanaminn-oxide
2-phenyl-n-tert-butylnitrone
alpha-phenyl-n-tert-butylnitrone
Benzylidene(tert-butyl)azane oxide
benzylidene-tert-butylaminen-oxide
c-phenyl-n-tert-butylnitrone
n-benzylidene-tert-butylamineoxide
n-tert-butyl-2-phenylnitrone
n-tert-butyl-alpha-phenyl-nitron
n-tert-butyl-c-phenylnitrone
N-tert-Butyl-α-phenylnitrone
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/03/03 | A17442 | N-叔丁基-α-苯基硝酮, 98% N-tert-Butyl-alpha-phenylnitrone, 98% | 3376-24-7 | 5g | 2566元 |
| 2026/03/03 | 17735 | N-叔丁基-α-苯基硝酮 N-tert-Butyl-alpha-phenylnitrone, 98%, Thermo Scientific Chemicals | 3376-24-7 | 1g | 877元 |
| 2025/12/22 | HY-128463 | N-叔丁基-#-苯基硝酮 N-tert-Butyl-α-phenylnitrone | 3376-24-7 | 5 mg | 158元 |
常見問題列表
|
COX-2
|
Reactive oxygen species (ROS)
|
N-tert-Butyl-α-phenylnitrone (PBN) (25-100 μM) treatment leads to a significant decrease in 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced intracellular ROS accumulation. N-tert-Butyl-α-phenylnitrone also attenuates AAPH-induced cytotoxicity, matrix degradation, and apoptosis. N-tert-Butyl-α-phenylnitrone suppresses AAPH-induced activation of ERK/MAPK pathway. N-tert-Butyl-α-phenylnitrone has the potenial for intervertebral disc degeneration (IDD) research.
N-tert-Butyl-α-phenylnitrone (PBN; 100 mg/kg; intraperitoneal injection; twice a day; C57Bl/6 mice) treatment not only abolishes the LPS-induced lipid peroxidation, nitrotyrosine residue levels, and GSH depletion, but also decreases the incidence of external malformations.
| Animal Model: | C57Bl/6 mice induced by lipopolysaccharide (LPS) |
| Dosage: | 100 mg/kg |
| Administration: | Intraperitoneal injection; twice a day (on gestational day 8) |
| Result: | Abolished LPS-induced lipid peroxidation, nitrotyrosine residues, and GSH depletion. |